

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: Erlotinib and Temozolomide in Treating Young Patients with Recurrent or Refractory Solid Tumors

OBJECTIVE OF STUDY: To determine the effectiveness of giving erlotinib with temozolomide to kill tumor cells

MINIMUM ELIGIBILITY REQUIREMENTS: Patients under 22 years of age

PARTICIPANT ACTIVITIES (*office visits, tests, take medications, etc*): Participants will receive erlotinib, by mouth, once a day. Beginning in week 5, they will also receive temozolomide by mouth once a day for 5 days every 4 weeks. Treatment will continue for as long as benefit is shown

CONTACT INFORMATION: **COORDINATOR / CHAIR** (*please circle one*)

NAME/TITLE: Dr. Regina Jakacki

AFFILIATION: Children's Hospital of Pittsburgh

MAILING ADDRESS: Pittsburgh, PA USA

PHONE: 412.692.5055

Email ADDRESS: regina.jakacki@chp.edu

WEBSITE (*for complete info*):

<http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=350336&version=patient>